Please provide your email address to receive an email when new articles are posted on . Results from a pilot randomized controlled trial showed Thalomid induced and maintained clinical remission in ...

A new study shows that Thalomid, from Celgene , can triple the amount of time patients with the blood cancer multiple myeloma can live without their disease worsening. The study is a victory for ...

Celgene thanked the woman who had the idea to use thalidomide as a treatment for multiple myeloma in its annual report, but says she isn't owed a dime for discovering the $2.2 billion-a-year treatment ...

A federal judge seems to be suggesting that Celgene (CELG) should settle a widow's lawsuit -- one in which the woman accused the company of not compensating her for discovering that Thalomid ...

Shares of Celgene were buoyed in overnight trading by news that the FDA had approved Thalomid as a therapy for the blood cancer multiple myeloma. Thalomid had originally been approved for leprosy but ...

Shares of Warren-based Celgene (Nasdaq: CELG) rose today after the company said its drug Thalomid, used in conjunction with a common therapy for fighting colorectal cancer, may improve the ...

April 3 (Reuters) - Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market. The lawsuit ...

BOSTON (Reuters) - The chief operating officer of Celgene Corp. said on Thursday he expects sales of the company's new cancer drug Revlimid to surpass sales of its older Thalomid treatment, but said ...

Celgene Corp. was accused of promoting its cancer drug Thalomid and related compound Revlimid for uses not approved by U.S. regulators in a newly unsealed lawsuit filed by a former saleswoman.

Drug Royalty Corp. has acquired a new royalty interest in the worldwide sales of Celgene Corp.'s Thalomid, for $4.7-million. The term of the agreement is tied to issued U.S. patents, the latest of ...

Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of dollars every year. And now it stands ready to take the stage on its own.

In 1996, Beth Jacobson was watching her husband, a 35-year-old cardiologist, die from the blood cancer multiple myeloma. She spent her nights reading medical journals at his bedside and her days ...